|  |
| --- |
| **Supplementary Table 2. Univariate biomarker analysis in endometrioid subtype cohort**  |
| Variable | Descriptive | RFS | OS |
|  | n (%) | HR (95%CI) | p-value | HR (95%CI) | p-value |
| ER NegativePositiveNE | 14 (5.4)236 (91.1)9 (3.5) | 0.45 (0.19 – 1.05) | 0.06 | 0.37 (0.16 – 0.88) | 0.02 |
| PRNegativePositiveNE | 20 (7.7)226 (87.3)13 (5) | 0.97 (0.39 – 2.44) | 0.95 | 0.79 (0.31 – 1.99) | 0.61 |
| ECADNegativePositiveNE | 35 (13.5)216 (83.4)8 (3.1) | 0.81 (0.38 – 1.70) | 0.57 | 0.69 (0.31 – 1.53) | 0.36 |
| HER2NegativePositiveNE | 258 (99.6)1 (0.4)- | NE | NE | NE | NE |
| ARID1ANegativePositiveNE | 191 (73.8)55 (21.2)13 (5) | 0.76 (0.41 – 1.43) | 0.4 | 0.83 (0.41 – 1.65) | 0.59 |
| PTENNegativePositiveNE | 174 (67.2)80 (30.9)5 (1.9) | 1.44 (0.87 – 2.40) | 0.16 | 1.47 (0.83 – 2.61) | 0.19 |
| L1CAMNegativePositiveNE | 235 (90.7)12 (4.6)12 (4.6) | 1.27 (0.40 – 4.09) | 0.68 | 1.71 (0.53 – 5.51) | 0.37 |
| *CTNNB1*Non mutatedMutatedNE | 223 (86.1)20 (7.72)16 (6.2) | 2.14 (1.05 – 4.34) | 0.04 | 1.55 (0.66 – 3.65) | 0.31 |
| NE: Not evaluable; HR: Hazard ratio; 95%CI: 95% Confidence interval; RFS: Relapse-free survival; OS: Overall survival. |